Drug news
Novo Nordisk withdraws Tresiba (insulin degludec) from Germany due to price negotiations
Novo Nordisk announced that the company has decided to cease distribution of its once-daily basal insulin Tresiba (insulin degludec) in Germany following a negative outcome of price negotiations with the GKV Spitzenverband, the German national association of statutory health insurance funds. In order to ensure a safe switch to another insulin treatment for the 40,000 people with diabetes currently using Tresiba, Novo Nordisk will continue supplying the product until the end of September 2015.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins